International Life Sciences Awards 2020
The Packages
Editor’s Choice Package 2,295GBP/ 3,006USD • MAIN front cover image and headline • 4 x Pages of dedicated content (Written in collaboration with our talented editorial team!) • 4 x Crystal trophies • 2 x Wall mounted plaques • Personalised digital logo • Personalised digital certificate • 8-Page bespoke digital brochure • 100 x Hard copies of your bespoke brochure • Bespoke press release • + Free of charge items
International Life Sciences Awards 2020
CERTIFICATE This is to certify that:
Company Name/Logo Have Been Named:
Award Title
DATE
Main front cover image and headline
Personalised Digital certificate Systasy Bioscience GmbH
Global Jetcare, Inc.
SIRE Life Sciences
Global Jetcare, Inc.
Provider – Europe & Best Cell-Based
Global Jetcare, Inc.:
Product: Custom targetSCREENER Assay
Ambulance - USA
Thanks to the extensive industry experience of its Senior Team, Systasy Bioscience GmbH acts as a unique Biotech company focusing on reviving drug discovery for complex brain disorders. To celebrate the firm winning not one but two of this year’s highly coveted work it undertakes in this crucial sector. Established in Such a service offering is vital in in pharma and biotech tool for assessing the activity of firm and explore the vital services itscientists provides. 2012 by a team of today’s healthcare and life sciences research to apply its High Content receptors as measured by the neuroscientists, market, as brain disorders are Profiling services for dissecting regulated binding to their cognate Thanks its award-winning Today, the firm is able to offer dedicated, molecular biologists the core to health challenge of the complex disease processes. cytosolic adapters. service offering and experienced specially trained pilots and medical personnel, and bioinformatic 21st century, primarily due to the personnel, since its launch GJC top-of-the-line medical equipment, scientists, Systasy is a contract demographic change. These services are highly and Seeking to continue to drive has gained the trust of hospitals, bedside-to-bedside service for a variety of research organization in the field innovative and offer a completely innovation in the brain disorder caseglobal workers and assistance patients. Operating 24 hoursdiscovery a day, seven of complex brain disorders. The economic burden of new approach to drug drug discovery market, looking companies CNS to transport their patients worldwide. week, GJC is able to EXTassay meet the needs ahead Systasy will be working diseases was estimated at days in athis field. The firm’s to of any patient, no matter how challenging Together the Founders share 2,5 trillion USD in 2010 - more technology lies at the core of the theyfurther increase mode-of-action may seem, and transport them around the knowledge the vision that recent scientific than cancer, cardiovascular High Content Profiling strategy for the identification in comfort. When a customer makes a insights in the genetics of disease and diabetes combined, world using genetically encoded of novel targets for first-in-class request to move a patient from one country brain disorders needs to be and is expected to increase to 6 biosensors in combination with drug discovery. As part of this clear across the globe GJC can provide complemented with a systemstrillion USD by 2030. next-generation sequencing focus the company will continue them with a timeline and cost in as little as level pharmacological strategy in (NGS) for highly multiplexed to expand its toolbox for in-depth 30 minutes, offering efficiency and ease for drug discovery. As a result, they Attempts to discover new phenotypic and phenogenomic mode-of-action and safety patients and their loved ones. drive this innovative company drugs for genetically complex screens. All cell signalling events profiling, which will help Systasy towards achieving truly lifebrain disorders, such as major are captured by molecularly to drive the life sciences market changing results. depression, schizophrenia barcoded reporters in one even closer towards providing and Alzheimer´s, have proven single experiment, resulting in viable relief to patients with a By developing an innovative extremely difficult. Insufficient measurements of large data variety of brain disorders. High Content Profiling strategy knowledge of the underlying sets. This technology allows to for target identification and lead biological mechanisms represents dissect the complex biology of optimization, which involves the a critical challenge impacting brain disorders in neurobiological usage of molecularly barcoded the drug discovery process. This test systems, such as in primary reporter gene assays in challenge is driving the need for mouse neurons and human patient-derived disease models, innovative technologies that can iPSC-derived disease models. Systasy aims to support the elucidate the complex cellular Contact Details: development of effective tailorcommunication in the early Additionally, Systasy’s made therapies. stages of drug discovery. splitSENSOR technology is a highly sensitive, flexible and At Systasy, the expert team easy-to-use reporter assay address this need by delivering system to monitor various cellular unmatched mode-of-action insights events in living cells, including the Company: through highly multiplexed profiling activity of drug targets. Various Systasy Bioscience GmbH services for target identification, cellular events, such as regulated Name: Dr. Sven Wichert, CEO lead optimization, and safety protein-protein interactions, can Address: Balanstr. 6, 81669 profiling. Working together with be robustly and quantitatively München, Germany some of the leading lights within measured both at the membrane Telephone Number: +49 (0) 89 the industry, the firm’s team and in the cytosol of the cell. This 2155 3085 collaborate with clinicians and feature makes it an invaluable Web Address: www.systasy.de
SIRE Life Sciences: Speed is of the essence in many critical cases, and as such GJC’s ability to move patients within as little as 24 to 48 hours is so important and unique. This swift turnaround gives customers the ability to ensure patients are moved to a higher level of care facility and also can be taken to their home country for care and to be with family.
Additionally, with so many regulations and rules, it is important to know the routing, permits and contracts to be able to navigate the world as safely and efficiently as possible, and as such GJC leverages its team’s expertise to ensure a safe flight every time.
Recently, GJC had its 5th Learjet put into service, and with worldwide capabilities the vehicle will allow the company to expand its operations even further in the future. The aircraft has been fully equipped with the latest avionics and advanced medical equipment to transport patients with special needs for long distances. As such, it will be able to help the firm to offer even more transports to patients around the world over the years to come.
Search & Recruitment Agency 2019 - Benelux Additionally, GJC has the ability to transport a family member with the patient at no additional cost. This is very important often to the stability of the patient and ensures that they feel safe throughout their flight.
All of these services are provided at accessible rates, enabling the firm to welcome a wide variety of patients and their families on board. Due to the high volume of transports GJC undertakes, the firm is able to offer customers optimum pricing by connecting multiple transports together. Often the company can give one-way pricing from locations as a savings of thousands of dollars to insurance companies and private families.
Ultimately, GJC is driven to provide the highest possible standard of care and service to patients, their families and insurance companies, and this will remain the firm’s core Patients and family members traveling with focus as it looks to a bright and opportunity GJC know that they are in truly safe hands. filled future. With demand for private air The firm’s flight coordinators are experts in ambulances increasing the firm has many Alongside its high number of transports, the what is required to move patients from one ® chances to grow and adapt to its customers’ Renowned specialist recruitment SIRE Life achieves unmatchedever-evolving results requirements. firm Sciences also benefits from its central location. country to another. GJC’sagency experienced flight Being based in Florida, GJC centrally located crewpartnering members have performed 1000’s of in talent placement, with Europe’s leading employers toisdeliver intelligent hiring Contact Details: between Asia, Europe, Canada and South patient transports. Their vast experience with America. This allows the firm the ability to move different types of patient conditions gives them Company: Global Jetcare, Inc. patients cost effectively from the United States the expertise required to react to unexpected Contact: Bart T. Gray , President to and from these locations. The team are also medical emergencies that can occur while Address: 15421 Technology Dr. able to move patients from non-US locations 40,000 feetAtinthe theheart air. of this strategy Founded in 2012, Brooksville, FL 34604 USA such as South America to Europe. SIRE Life Sciences is the belief that recruitment Their vast knowledge on howthe to use Phone: +1-352-799-7771 has since established goes far beyond placement For those patients that are traveling from applications translate any language allows Email: quote@globaljetcare.com itself as a key player ofto candidates. Effective further afield, GJC’s collaborative approach them to communicate around the world. globaljetcare.com in the life sciences employment solutions need This is ensures that they receive the standard of critical to working with personnel from airports, recruitment market. to put the right person in the service and support they need. The company hospitals, ambulance services astime, well as relevant place every using has partnered with other trusted Air Ambulance family members, ensures that Today the firm is among thepatients and advanced systemsand to streamline companies from locations such as China, every flight goes completely according to plan most innovative and engaged costs and time-frames for clients. India, Europe and South America to perform and that everyone involved feels comfortable recruitment and executive search As such, these values are at wing-to-wing transfers when time is of the and supported when they fly with GJC. company for the life sciences the heart of SIRE Life Sciences’ essence or the patients’ condition is better industries. The company service offering. treated by local experts. achieves unmatched results in talent placement, partnering Overall, SIRE Life Sciences’ with Europe’s leading employers dedication to combining and providing comprehensive cutting-edge technology with a premium search services for personal approach to recruitment industry professionals. and specialist knowledge of the needs of employers across Operating in a competitive the life sciences market has market, SIRE Life Sciences propelled the firm to the top of has set itself apart from its this flourishing industry. Moving competitors by using the latest forward the firm will continue to technology to reduce risk and innovate and adapt its service add assurance to the recruitment offering to meet the ever-evolving process, rather than simply needs of this fast-paced market relying on guesswork. to ensure clients and candidates alike receive the support they Using these tools, SIREneed to drive the life sciences Life Sciences has developed market forward. the concept of Reverse Recruitment©. This approach reduces time-frames and Contact Details: improves talent acquisition for companies by mapping the Company: SIRE Life Sciences entire market in-depth before Contact: Jordy Stravers employment needs arise. Website: https://sire-search.com/
coordinators are experts in what is required to
country to another...
members traveling with GJC know that they are in truly safe hands...
“GJC’s experienced
have performed 1000’s Their vast experience
required to react to unexpected medical emergencies that can occur while 40,000 feet in the7 air.”
GHP
6 4
GHP
5
Four pages of editorial 2x Mounted Wall Plaques
Company Name
International Life Sciences Awards 2020 Award Title
Personalised Digital Logo
4x Crystal Trophies
The Tertiary Package 1,095GBP/ 1,434USD • Supporting front cover image and headline • 2 x Pages of dedicated content (Written in collaboration with our talented editorial team!) • 2 x Crystal trophies • 1 x Wall mounted plaque • Personalised digital logo • Bespoke digital certificate • 4-Page bespoke digital brochure • 50 Hard copies of your bespoke brochure • + Free of charge items
Personalised digital logo
Company Name Personalised digital certificate
International Life Sciences
International Life Sciences Awards 2020
Awards 2020
CERTIFICATE
Award Title
This is to certify that:
Company Name/Logo Have Been Named:
Wall mounted plaque
Award Title
DATE
Supporting front image and deadline
LI180003
Best Allergy-Focused Medtech Company 2018 Xavier Guillem to talk us through the vital work that this dynamic, user focused firm undertakes.
Adan Medical Innovation was born in 2014, when, after participating in an innovation program in Silicon Valley, at Imagine Creativity Center, the firm’s founders were able to mature their ideas. The team firmly believe in the phrase ‘if you want to go fast go alone, but if you want to go far go together’. With this in mind, they set out to be a different health tech company, and created a multidisciplinary team with experts in all the different areas that the project needed, including clinical, business, regulatory, hardware and software, quality control, design, and crucially, patients, to be able to bring excellence to the project. Xavier
explores the achievements that the firm has made since inception and the strides it is making towards changing the lives of allergy suffers for the better.
“From our humble origins, today Adan Medical Innovation is flourishing, and we are now working towards the mission to improve the quality of life of patients that suffer from severe allergic reactions requiring epinephrine by creating integrated digital solutions. We have developed two medical devices, the first of which is geared towards individual patients, which is a smart case for epinephrine auto-injectors connected to a cell phone, resolving the main limitations of these auto-injectors. Our second solution is a disruptive
IoT solution, a smart box for epinephrine auto-injectors in public places like schools, restaurants, and shopping malls, in case the patient does not have one with them or it is the first time they have a reaction. “Over the years since we founded our company, our team has grown and worked very hard, always with the purpose to improve the development of our solution. The first clinical trial for a medical device evaluating its usefulness for the management of anaphylaxis has been completed in one of the largest hospitals in Europe. Currently, with the improved solution and the clinical trial completed, we are working in the last steps to bring anAPPhylaxis (the smart case) to the market, and we
4
anticipate it will be possible by Q1 2019. We are also preparing a School Test Program to test our emergency box in several schools from Europe and U.S. before we launch it to market, and we are recruiting schools where we could perform the study. With our product, anaphylaxis at school or in public spaces will never be the same again.” Overall, having achieved such incredible success, Adan Medical Innovation is keen to carry on and build upon its current achievements to ensure that it achieves its long term goals, as Xavier concludes.
“Looking ahead, alongside our initial solutions, we are now working on other solutions in the anaphylaxis market in order
to give the best assistance to people suffering from lifethreatening allergic reactions, as well as in a system to collect all this data coming from the consumer of our products that will be used by doctors and manufacturers of epinephrine auto-injectors in order to issue recalls, etc. We also have the
opportunity to move forward and start exploring other areas. Our products could be perfectly adapted in a future to other conditions, which makes our idea very valuable, and as such we have long term plans to move into new markets once we have achieved our goals in the anaphylaxis space.”
Company: Adan Medical Innovation Contact: Xavier Guillem Address: Anglí, 31. 4-1, Barcelona, 8017, Spain Phone: 34 932 188 882 Website: www.adanmi.com
GHP
5
Two pages of editorial 2x crystal trophies
The Secondary Package 795GBP/ 1,014USD • Your company logo on the front cover • 1 x Page of dedicated content (Written in collaboration with our talented editorial team!) • 1 x Crystal trophy • Personalised digital logo • Bespoke digital certificate • + Free of charge items 1x crystal trophy
Front Cover Logo
Full page of editorial
International Life Sciences Awards 2020
CERTIFICATE
Agxio
Recognised Leaders in Enterprise Behavioural
This is to certify that:
Company Name/Logo Have Been Named:
Award Title growth investment. We profile the latest Neural Insights firm, Agxio and explore how CEO Founded in July 2018, Agxio has emerged as a leader in the life sciences, analytics and machine learning field applied to AgriTech and AgriFinTech.
DATE
As Founder, CEO and Partner, Dr. Stephen Christie is deeply committed to driving the firm towards even greater success. He specialises in Strategy, Technology, AI, Blockchain, Quantitative, Legal, Analytics, Digital, Surveillance and
8
Company Name
International Life Sciences Awards 2020
Incubated by Neural Insights, recognised leaders in the fields of artificial intelligence, machine learning, digital and data science, quantitative modelling and cybertechnologies, the firm is able to meet the needs of a diverse range of clients and provide them with cutting-edge solutions. For each and every client the firm supports, its objectives are to stimulate economic growth by improving their enterprise performance, acting as a catalyst for growth opportunities, improving risk management processes, promoting innovation, and delivering high performance transformation across the business.
Personalised digital logo
Award Title Behavioural Science, as well as Risk and Regulation. Thanks to this wide-ranging expertise, Stephen is able to drive Agxio to success and ensure every project is completed to the high standard the firm’s clients expect and rely on. Globally, his team’s results have contributed billions of dollars
to the world economy. With experience in nearly 40 countries across the globe, his teams have delivered within the major consulting brands and have partnered with the elite to create solutions that have impact and sustainable board level results. Ultimately, Agxio measures its success by the success of its clients, and as such driving them
to even greater achievements will remain the firm’s core objective as it looks ahead towards a bright, opportunity-filled future.
Contact: Dr. Stephen Christie Website: www.agxio.com
Personalised digital certificate
The Primary Package 495GBP/ 648USD • 1 x Page of dedicated content (Written in collaboration with our talented editorial team!) • 1 x Crystal trophy • Personalised digital logo • + Free of charge items
Company Name
International Full page of editorial
Life Sciences
Awards 2020
Best Chronic Disease Novel Therapies Developers - Europe: Alphanosos
Award Title
Alphanosos
Established in 2015, Alphanosos discovers, patents and produces botanical preparations with antimicrobial and anti-cancer properties. These innovative actives are based on synergistic mixes of Water Extracts of Complex Mixes of Edible Plants (WECMEPs). These blends are selected and optimized with the firm’s own Artificial Intelligence algorithms and rapid discovery platform. These discoveries will eventually be confirmed as ground-breaking treatments, especially for chronic diseases, and mark the beginning of a legacy of success in this market for Alphanosos, as Pascal explains in his opening comments.
“At Alphanosos our patent pending WECMEPs are incorporated into commercial products and generate its first revenues. Our first products are veterinary hygiene products and human cosmetics. WECMEPs are also evaluated as additives for aquaculture and animal feed in general. Later, we will use them in dietary supplements and finally as drugs. The initial target diseases will be bacterial infections, in particular those responsible for certain chronic inflammations, starting with skin affections, and those resistant to conventional antibiotics, and cancers. These short term products will lead us to our ultimate vision of providing health preservation products personalized on the basis of somatic and microbiota genetic profiles and Artificial Intelligence.”
As part of its drive towards innovation in the life sciences market, Alphanosos is aiming to collaborate with a range of other companies to create unique solutions, as Pascal highlights.
“Seeking to support our peers in the market, we are offering partnerships on the discovery of specialized WECMEPs. The life science industry has yet to realize the potential of this approach, which allows to develop “Botanial Drugs” (FDA) which are eligible for direct entry into phase II (USA). The animal feed industry starts already realizing the enormous potential of the rapid development of actives made of botanicals already registered as feed additive.” As he concludes his comments, Pascal is keen to discuss the future and how his firm will continue to work towards innovation.
“Looking ahead, the immediate future for Alphanosos will revolve around expanding our veterinary hygiene product line and launching our dermocosmetic products. Next will be alternatives to antibiotics for animal feed additives and also functional foods, drinks and food preservatives. Alphanosos is studying many other applications to its proprietary technology like natural antibiotics for animals and humans (gonorrhoea, tuberculosis, antimicrobial resistance),
Personalised digital logo
preventive and curative oncology, biodefense and, based on somatic and microbiota genetic profiles, personalized prevention of microorganism induced chronic inflammatory diseases such as Lyme’s, Alzheimer’s, atherosclerosis, inception of certain cancers, etc. It is also envisioned to work with partners on viruses such as seasonal flu, and also pain, inflammation, aging, etc. “Overall, all of these benefits will help drive Alphanosos towards greater industry renown and showcase our innovative approach towards novel therapies. We strongly believe that WECMEPs will be the future of pharma industry: turning from hazardous and polluting ‘first time in the universe’ single compounds towards nearly certainly safe and biodegradable system’s biology therapies. We are already driving this revolution and we look forward to seeing it through.” Contact Details: Company: Alphanosos Name: Pascal Mayer Address: 20-22 rue Henri et Gilberte Goudier, 63200 Riom, France Phone: +33 982 211 049 Web Address: alphanosos.com
14
1x crystal trophy
Individual Items: Crystal trophy: 245 GBP/ 320 USD Slate trophy: 245 GBP/ 320 USD Wall plaque: 245 GBP/ 230 USD Personalised digital logo: 185 GBP/ 242 USD Personalised digital certificate: 185 GBP/ 242 USD
Wall Plaque
Slate Trophy
Personalised digital logo
Company Name
International Life Sciences Awards 2020 Award Title
Crystal trophy